Figure 3.
Simulations of five rituximab pharmacokinetic profiles using typical pharmacokinetics parameters, (A) increasing CD19 counts (10 to 500 mm−3), (B) increasing serum IgG concentrations (5 to 25 g l–1), and (C) for rituximab courses 1–5 showing time‐dependence of rituximab pharmacokinetics